Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Nvidia’s momentum has been weighed down by cooling AI hype and broader market instability. Despite reporting blockbuster Q4 ...